Double heterozygotes were more likely to be diagnosed with breast cancer compared to women with only one deleterious BRCA pathogenic variant (68.1% vs. 52.0% for BRCA1, p = 0.002; 67.4% vs. 50.4% for BRCA2, p = 0.002). The gene discussed is BRCA2; the disease is breast cancer.